SCHEMBL27113249

SCHEMBL27113249

CN1CCN(c2cccc(CNC(=N)N)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AGXT P21549 1/20 0.57
▸ ADRA2C P18825 1/20 0.51
▸ PRMT6 Q96LA8 1/20 0.49
▸ MAPK14 Q16539 1/20 0.48
▸ ITGB3 P05106 2/20 0.46
▸ ITGA2B P08514 2/20 0.46
▸ CCNA2 P20248 2/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CCNA1 P78396 2/20 0.45
▸ SIRT6 Q8N6T7 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ PLOD2 O00469 1/20 0.43
▸ PLOD3 O60568 1/20 0.43
▸ PLOD1 Q02809 1/20 0.43
▸ HTR6 P50406 3/20 0.43
▸ HRH4 Q9H3N8 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27114131 0.86 ITGB3 (0.46) AGXTPRMT6ITGB3ITGA2BMEN1
SCHEMBL27113417 0.86 PRMT6 (0.46) AGXTPRMT6MAPK14ITGB3ITGA2B
SCHEMBL27120294 0.86 PRMT6 (0.46) AGXTPRMT6ITGB3ITGA2BMEN1
SCHEMBL27113243 0.84 PRMT6 (0.47) AGXTPRMT6ITGB3ITGA2BMEN1
SCHEMBL27113244 0.84 HTR7 (0.49) PRMT6ITGB3ITGA2BHTR6MAPT
SCHEMBL27118870 0.83 PRMT6 (0.46) AGXTPRMT6MAPK14ITGB3ITGA2B
SCHEMBL27114252 0.83 PRMT6 (0.43) AGXTPRMT6MAPK14ITGB3ITGA2B
SCHEMBL38666373 0.82 HTR2A (0.56) AGXTADRA2CPRMT6MAPK14CCNA2
SCHEMBL27113245 0.79 SMN1; SMN2 (0.53) ITGB3ITGA2BMEN1LMNAMAPT
SCHEMBL27114133 0.78 ITGB3 (0.43) ITGB3ITGA2BMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066135-A1 DRUG CONJUGATES AND USES THEREOF SUPERTRANS MEDICAL LTD (IL) 2024-02-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240066135-A1 DRUG CONJUGATES AND USES THEREOF SLC7A1, ABCB11, SLC1A5 AGXT 282/4885ADRA2C 3508/4885PRMT6 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback